Early and maintained application of the secretion of Cryptomphalus aspersa (SCA) 40% improves cutaneous healing after ablative fractional laser in skin aging.

BACKGROUND: Ablative fractional laser generates a regulated skin damage, which secondarily improves skin aging. AIMS: The main objective of the present study was to figure out if the adverse effects induced by laser and the skin recovery could improve with the application of a cosmetic product based on the secretion of Cryptomphalus aspersa (SCA). PATIENTS/METHODS: A prospective double-blind controlled study with vehicle in 10 patients with skin aging. The patients received one session of fractional ablative CO2  laser, and the formulation with SCA 40% was applied immediately and maintained throughout the 21-day duration of the study. The active treatment (SCA) was applied to one hemifacial area and vehicle to the other, and the patient acting was her own control. Clinical evaluations, dermoscopy, photography, and other parameters like cutaneous hydration, elasticity, and wrinkles were evaluated. In addition, the severity of the adverse effects was evaluated. RESULTS: Significant greater decrease in the density of microcolumns produced by laser was detected on the active-treated side, indicating greater and faster postprocedure recovery compared to the vehicle-treated side. In addition, side effects were reduced and some antiaging effects were more apparent on the side treated with SCA 40%. CONCLUSION: SCA 40% applied immediately after ablative laser, and during the next days, it can accelerate laser-induced damage regeneration. In addition, SCA improves the cosmetic outcome after laser application.

A cosmetic treatment based on the secretion of Cryptomphalus aspersa 40% improves the clinical results after the use of nonablative fractional laser in skin aging.

INTRODUCTION: The main purpose of this study was to evaluate whether the application of a cosmetic treatment based on the secretion of Cryptomphalus aspersa (SCA) enhances the clinical results, tolerance, and skin regeneration after nonablative laser treatment in patients with moderate photoaging. METHODS: Randomized, double-blind, split-face trial in 20 patients with moderate aging. Two sessions with fractional nonablative laser were performed, and the cosmetic treatments (SCA 40% on one hemiface and vehicle on the other) were applied immediately after laser session and daily during the study (28 days). Tewameter, Cutometer, Visioscan, VisioFace, photography, dermoscopy, and clinical evaluation were assessed. Side effects were also evaluated. RESULTS: A significant decrease in the density of microcolumns (25%, 71%, 32%, and 61% less density, respectively, at T3 P = 0.008, T7 P = 0.002, T22 P < 0.001, and T24 P < 0.001) was observed on the side treated with SCA compared to the vehicle-treated side. Cutaneous elasticity, area of wrinkles, and hydration on the SCA-treated side also showed a significant improvement compared to the vehicle-treated side. Both the researcher and patients observed a significant improvement on the side treated with SCA compared to the vehicle-treated side. Significantly fewer side effects (erythema, burning, and dryness) were also detected. CONCLUSION: A cosmetic product with SCA 40% applied immediately after laser and for a period thereafter enhances and accelerates repair of damage produced by the laser and significantly reduces related adverse effects. In addition, SCA treatment could improve clinical results. In conclusion, we suggest that SCA enhances the effectiveness of laser in the treatment of cutaneous aging.